Clinical Trials on Breast Implant in Belgium

Total 586 results

Pfizer

Terminated

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Breast Neoplasms

United States, Canada, Netherlands, Brazil, Belgium, United Kingdom, Argentina, Italy, Sweden
Daiichi Sankyo, Inc.
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Breast Cancer

United States, Spain, Italy, Korea, Republic of, Belgium, France, Japan, United Kingdom, Canada
Hoffmann-La Roche

Completed

Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer

Breast Cancer

Hungary, Italy, Spain, France, United Kingdom, Belgium, Germany, Portugal, Poland, Canada, Bulgaria, Mexico
ETOP IBCSG Partners Foundation
Alliance for Clinical Trials in Oncology; Canadian Cancer Trials Group; Breast...

Active, not recruiting

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer (POSITIVE)

Early Breast Cancer

Korea, Republic of, United States, France, Canada, Spain, Lebanon, Belgium, Switzerland, Israel, Ireland, Japan, Italy, Denmark, Austria, Australia, Greece, Hungary, Netherlands, Norway, Portugal, Serbia, Slovenia
Eisai Inc.

Completed

E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Metastatic Breast Cancer

Poland, Ukraine, United States, Taiwan, Spain, Argentina, Bulgaria, Romania, South Africa, Australia, Canada, Singapore, Russian Federation, Brazil, Germany, Hungary, Italy, Israel, Greece, Mexico, Belgium, Czechia, France
AstraZeneca
SWOG Clinical Trials Partnerships; Daiichi Sankyo

Recruiting

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Breast Cancer

United States, China, Denmark, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Belgium, Spain, Japan, France, Taiwan, Greece, Brazil, Sweden, Puerto Rico
Novartis Pharmaceuticals

Completed

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

Breast Cancer

Canada, Italy, Czechia, United States, Belgium, Austria, Germany, Spain, Japan, Lebanon, Australia, Bulgaria, Israel, Netherlands, Colombia, Hong Kong, Brazil
ADC Therapeutics S.A.

Terminated

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Pancreas Cancer | Colo-rectal Cancer | Triple-negative Breast Cancer | Head and Neck Cancer Squamous Cell Carcinoma

United States, Belgium, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. (MONALEESA-3)

Advanced Breast Cancer

Belgium, Italy, Czechia, Hungary, Canada, Netherlands, Germany, Singapore, Australia, Denmark, Poland, Switzerland, Korea, Republic of, Spain, Thailand, Lebanon, Austria, Bulgaria, Russian Federation, Norway, Jordan, United States, ... and more
Novartis Pharmaceuticals

Completed

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (BOLERO-3)

Metastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast Cancer

China, United States, France, Hungary, Turkey, Japan, Germany, Singapore, Italy, Poland, Spain, United Kingdom, Thailand, Israel, Australia, Belgium, Greece, Argentina, Czech Republic, Mexico, Slovakia
AbbVie

Completed

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, Denmark, Finland, France, Hungary, Israel, Netherlands, Norway, Poland, Romania, Russian Federation, Spain, Sweden, Ukraine
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve)

Breast Cancer

United States, Belgium, Italy, Spain, United Kingdom, Taiwan, Canada, Germany, Argentina, Israel, Korea, Republic of, Denmark, France, India, Chile, Netherlands, Singapore, Japan, Mexico
Genentech, Inc.
Breast International Group; SOLTI Breast Cancer Research Group; Austrian Breast...

Completed

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

Breast Cancer

United States, United Kingdom, Germany, Australia, Austria, Belgium, Brazil, France, Guatemala, Italy, Korea, Republic of, Panama, Poland, Portugal, Spain, Czechia, Hungary, Mexico, Peru, Switzerland, El Salvador, Chile
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Triple Negative Breast Cancer

United States, Korea, Republic of, Belgium, Canada, Germany, United Kingdom, Argentina, Australia, Brazil, Finland, France, Greece, Hungary, Poland, Slovenia, Spain, Taiwan, Turkey, Japan, Singapore, Colombia, Bosnia and Herzegovina, Guatema... and more
Novartis Pharmaceuticals

Terminated

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi (BELLE-3)

Metastatic Breast Cancer

United States, Germany, Belgium, Canada, France, Italy, Spain, United Kingdom, Austria, Argentina, Sweden, Hungary, Korea, Republic of, Lebanon, Bulgaria, Greece, Thailand, Netherlands, Colombia, Norway, Finland, Poland
University Hospital, Antwerp

Completed

Dendritic Cell Vaccination for Patients With Solid Tumors

Renal Cell Carcinoma | Glioblastoma | Malignant Mesothelioma | Colorectal Tumors | Breast Cancers | Sarcomas

Belgium
AstraZeneca

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

Breast Cancer, Early Breast Cancer

United States, Canada, United Kingdom, China, Argentina, Australia, Hungary, Netherlands, Korea, Republic of, France, Germany, Italy, Belgium, Bulgaria, India, Mexico, Spain, Vietnam, Colombia, Japan, Peru, Brazil, Malaysia, Taiwan, Tha... and more
Genentech, Inc.

Completed

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy

Breast Cancer

Belgium, Israel, United States, Spain, Denmark, Germany, Hong Kong, Russian Federation, Australia, New Zealand, Korea, Republic of, Malaysia, Singapore, Italy, Czech Republic, France, Peru, Canada, United Kingdom, Chile, Thailand, Argentin... and more
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07)

Stage IV Breast Cancer | Locally Advanced or Unresectable Metastatic Breast Cancer

Taiwan, Korea, Republic of, Australia, Greece, Spain, United States, United Kingdom, France, Israel, Malaysia, Japan, Belgium, Poland, China, Germany, Czechia, Singapore, Hungary, Brazil, Italy, South Africa, Portugal, Argentina, Hong... and more
Pfizer
AstraZeneca

Completed

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

Metastatic Breast Cancer

Korea, Republic of, United States, Canada, United Kingdom, Australia, Taiwan, Netherlands, Italy, Japan, Belgium, Ireland, Ukraine, Portugal, Germany, Romania, Russian Federation, Turkey
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (MONALEESA-7)

Advanced Metastatic Breast Cancer

Canada, Italy, Hungary, Taiwan, Turkey, Belgium, Germany, Spain, United States, Singapore, Australia, Korea, Republic of, Hong Kong, Thailand, Lebanon, Bulgaria, France, Russian Federation, Argentina, Brazil, Malaysia, Portugal, Col... and more
AstraZeneca
Daiichi Sankyo

Recruiting

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Breast Cancer

United States, Spain, United Kingdom, Korea, Republic of, Philippines, Canada, Germany, Italy, Poland, Belgium, Mexico, Japan, France, Brazil, Taiwan, Thailand, Hungary, Turkey, China, India, South Africa, Singapore, Argentina
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) (MONALEESA-2)

Advanced, Metastatic Breast Cancer

United States, Canada, France, Italy, Spain, Taiwan, Hungary, Turkey, Belgium, Germany, Netherlands, Singapore, Austria, Czechia, Australia, Israel, Russian Federation, Sweden, United Kingdom, Korea, Republic of, Thailand, Lebanon, ... and more
Hoffmann-La Roche
Breast International Group; Frontier Science & Technology Research Foundation... and other collaborators

Completed

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030)

Triple Negative Breast Cancer

Russian Federation, United States, Israel, Italy, Spain, France, Korea, Republic of, United Kingdom, Denmark, Taiwan, Hungary, Argentina, Australia, Austria, Belgium, Brazil, China, Germany, Hong Kong, Japan, Mexico, Romania, Switze... and more
ETOP IBCSG Partners Foundation
Breast International Group

Completed

Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer (SOLE)

Breast Cancer

France, Spain, Switzerland, Australia, Belgium, Austria, Peru, Germany, Italy, Japan, New Zealand, Sweden, Denmark, India, United States, Chile, Russian Federation, United Kingdom, Hungary, South Africa
AstraZeneca
Austrian Breast and Colorectal Cancer Study Group (ABCSG)

Recruiting

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (CAMBRIA-2)

Breast Cancer, Early Breast Cancer

United States, Spain, Italy, Korea, Republic of, Belgium, Poland, Portugal, United Kingdom, France, Canada, China, Germany, Japan, Mexico, Thailand, Hungary, Australia, Brazil, Colombia, Greece, Taiwan, Malaysia, Philippines, Austria, R... and more
Novartis Pharmaceuticals

Recruiting

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. (EPIK-B5)

Breast Cancer

Germany, Italy, Belgium, Denmark, France, Spain, Finland, Hungary, Ireland, Czechia, Greece, Canada, Portugal, Slovakia, Bulgaria, Poland, Romania
AstraZeneca

Recruiting

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) (CAPItello-292)

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Spain, Denmark, United States, Korea, Republic of, Germany, Belgium, Vietnam, United Kingdom, France, Japan, Canada, China, India, Malaysia, Taiwan, Thailand, Australia, Turkey, Argentina, Brazil, Poland, Sweden, Italy
Sanofi
Cancer International Research Group (CIRG)

Completed

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Breast Neoplasms

United States, France, Brazil, Romania, Russian Federation, Australia, Spain, Sweden, Turkey, India, Slovakia, Taiwan, Belgium, Czech Republic, Tunisia, Uruguay, Argentina, Croatia, Austria, Egypt, Greece, Hungary, Ireland, Israel, Italy, Mexic... and more
Amgen

Completed

Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

Locally Recurrent and Metastatic Breast Cancer

United States, United Kingdom, Denmark, Poland, Belgium, Hungary, Spain, Austria, France, Australia, Netherlands, Finland, India
Daiichi Sankyo, Inc.
AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...

Active, not recruiting

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

HER2-Positive Primary Breast Cancer | Residual Invasive Breast Cancer

United States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
Hoffmann-La Roche

Completed

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Breast Cancer

Spain, United Kingdom, Belgium, Austria, Brazil, France, Germany, Hungary, Italy, Thailand, Korea, Republic of, Hong Kong, Romania, Canada, Argentina, Czechia, Peru, Estonia, Mexico, Poland, Russian Federation, Croatia, Netherlands
Seagen Inc.

Recruiting

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

HER2-positive Breast Cancer

United States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
AstraZeneca
Daiichi Sankyo

Active, not recruiting

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Breast Cancer

Belgium, Canada, France, Italy, Spain, United Kingdom, Hungary, Poland, United States, Korea, Republic of, Brazil, India, Japan, Russian Federation, China, Taiwan, Netherlands, Germany, South Africa, Argentina
Novartis Pharmaceuticals

Completed

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation (BELLE-4)

Breast Cancer

Belgium, France, Taiwan, Hungary, Germany, Singapore, Austria, Netherlands, Australia, Russian Federation, Spain, Canada, Israel, Japan, Korea, Republic of, Italy, United States, United Kingdom, Brazil, Hong Kong, Czech Republic, South...
Seagen Inc.

Completed

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer (HER2CLIMB)

HER2 Positive Breast Cancer

United States, Spain, Belgium, Germany, Israel, France, United Kingdom, Austria, Denmark, Italy, Australia, Canada, Czechia, Portugal, Switzerland
Puma Biotechnology, Inc.

Completed

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)

HER2+ Metastatic Breast Cancer (MBC)

United States, Canada, Spain, Singapore, Korea, Republic of, Taiwan, United Kingdom, Israel, Australia, Japan, Hong Kong, Finland, Ireland, Italy, France, Portugal, Germany, Sweden, Belgium, Brazil, Czechia, Switzerland, Argentina, Au... and more
GlaxoSmithKline

Terminated

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer (INDUCT)

Neoplasms, Breast

United States, Belgium, United Kingdom, Germany, Russian Federation, Italy, France
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Locally Advanced or Metastatic Breast Cancer

France, Belgium, United States, Korea, Republic of, Taiwan, Brazil, China, Italy, Argentina, Jordan, Mexico, Germany, Portugal, Spain, Thailand, United Kingdom, Kenya, Turkey, Hungary, Colombia, India, Oman, Saudi Arabia, Poland, Uganda, United... and more
Boehringer Ingelheim

Completed

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

Breast Neoplasms

Spain, United States, Belgium, Italy, Germany, France, Greece, United Kingdom, Portugal, Australia, Canada
AstraZeneca

Completed

Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

Breast Neoplasms

United States, Australia, Brazil, South Africa, Spain, United Kingdom, Argentina, Belgium, Canada, France, Germany, Denmark
Seagen Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)

HER2 Positive Breast Cancer

United States, Taiwan, Canada, Korea, Republic of, Austria, China, Spain, Japan, France, Italy, Switzerland, Australia, Belgium, Brazil, Germany, Portugal, United Kingdom, Netherlands, Czechia, Greece, Chile, Finland, Poland
AstraZeneca
Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo

Active, not recruiting

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06)

Advanced or Metastatic Breast Cancer

United States, Belgium, Canada, Denmark, France, Italy, Spain, Hungary, Poland, Taiwan, Russian Federation, Germany, Korea, Republic of, Brazil, Japan, Mexico, United Kingdom, China, Israel, Austria, Australia, Saudi Arabia, Netherl... and more
Hoffmann-La Roche

Completed

A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin

Breast Cancer

Italy, Austria, Belgium, Germany, Spain, United Kingdom, Hungary, Poland, Sweden
European Organisation for Research and Treatment...
Hoffmann-La Roche; UNICANCER; Janssen Diagnostics, LLC; SUCCESS

Completed

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer (TREAT-CTC)

Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Circulating Tumor Cells

France, Germany, Belgium, United Kingdom
Novartis Pharmaceuticals

Completed

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. (BOLERO-6)

Breast Cancer

Belgium, Hungary, Spain, Argentina, Russian Federation, Sweden, Lebanon, Australia, Denmark, Ireland, United Kingdom, Thailand, Turkey, Peru, Brazil, Malaysia, India, United States
Genentech, Inc.

Completed

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer

United States, Korea, Republic of, Australia, Austria, Czechia, United Kingdom, Belgium, Spain
AstraZeneca

Active, not recruiting

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4)

ER-Positive HER2-Negative Breast Cancer

Austria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (INAVO121)

Breast Cancer

Canada, Belgium, Korea, Republic of, United States, China, Taiwan, Mexico, Brazil, Argentina, Australia, Italy, Spain, Turkey, Thailand, United Kingdom, Poland, South Africa
Celcuity, Inc.

Recruiting

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (VIKTORIA-1)

Breast Cancer

Korea, Republic of, United States, Belgium, United Kingdom, Taiwan, France, Italy, Australia, Singapore, Argentina, Canada, India, Mexico, Czechia, Spain, Austria, Bulgaria, Germany, Hungary, Poland, Brazil, Greece, Romania

Clinical Trials on Breast Implant in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations